Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Parkinson Disease 4, Autosomal Dominant Lewy Body 21Breast Neoplasms 17Neoplasms 16Multiple Myeloma 16Leukemia, Myeloid, Acute 15Recurrence 10Colorectal Neoplasms 10Myelodysplastic Syndromes 9Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Lymphoma, Follicular 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Stomach Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Purpura, Thrombocytopenic, Idiopathic 5Neoplasm Metastasis 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Graft vs Host Disease 5Esophageal Neoplasms 5Bronchiolitis Obliterans Syndrome 5Adenocarcinoma 5

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has announcements × Pathologic Processes × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡